Imaging Mass Cytometry furthers important immune response investigations
Advancements in the field of immuno-oncology have bolstered our understanding of immune responses and accelerated immuno-oncology research. Leading researchers apply key tools and technology, including Imaging Mass Cytometry™ (IMC™), to advance biomarker discovery and development and to better understand how the immune system responds to cancer and potential immunotherapy treatments.
High-multiplex imaging to investigate the spatial biology of the complex tumor microenvironment (TME) now plays a clear role in advancing these immuno-oncology studies.
No CyTOF? No problem.
We can help you convert your fluorescence panel and find a service provider.
New in IMC for immuno-oncology
When speed matters, get faster answers for cohort analysis and clinical studies with the second-generation Hyperion+™ Imaging System.
The IMC Trending Topics in Immuno-Oncology article covers the latest research and past publications using IMC to explore the tumor-immune landscape, biomarker discovery and methods associated with therapeutics development.
In this immuno-oncology e-book, two articles selected from Drug Target Review highlight findings that researchers believe could be used to enhance immunotherapies. This is supplemented with a short Expert View article by Standard BioTools™ Chief Science Officer Andrew Quong, PhD.
The IMC immuno-oncology bibliography has over 50 publications through March 4, 2022, that highlight the use of IMC to investigate the spatial biology of the complex tumor microenvironment and its role in furthering immuno-oncology research.
Gaining an accurate understanding heterogeneity and phenotypes in the TME
The Hyperion™ Imaging System is a high-multiplex single-cell imaging solution that has proven use in characterizing the immune repertoire in the TME. Nearly 40% of the over 130 peer-reviewed publications using the Hyperion Imaging System have been in translational or clinical research focused on cancer and immuno-oncology.
Two decisive presentations were delivered in the Publications Spotlight session at our October 2021 event IMC Summit: Uncovering Spatial Biology.
Immuno-Oncology Panel Kits for Imaging Mass Cytometry
Maxpar® panel kits for detection of human tumor-infiltrating lymphocytes, immune activation, and tissue architecture provide researchers with a richer, more insightful understanding of the cancer-related processes in the tumor microenvironment.
Expert insight on the transformation of precision medicine
Olivier Elemento, PhD
Professor, Physiology and Biophysics, Weill Cornell Medicine
Director, Englander Institute for Precision Medicine
Oliver Elemento shares his expert insight on the transformation of precision medicine. In this short video, Elemento describes why artificial intelligence, high-throughput sequencing and Imaging Mass Cytometry are becoming increasingly critical tools for personalizing treatments and improving patient outcomes.
Learn about the multi-collaborative Tumor Profiler Study
Read the Cancer Cell article “Tumor Profiler Study: Integrated multi-omic, functional tumor profiling for clinical decision support” and hear Bernd Bodenmiller discuss his lab’s role in this multi-site collaborative project. The author suggests how technologies like IMC could be used to contribute to oncological clinical decision-making in the future.
Insights into how IMC could impact prognosis in the future
The conclusion from the Xie et al. publication “Hyperion image analysis depicts a preliminary landscape of tumor immune microenvironment in OSCC with lymph node metastasis” states “The Hyperion Imaging System helped to delineate a preliminary and multidimensional landscape of the tumor immune microenvironment in OSCC with lymph node metastasis and provided insights into the influence of the immune microenvironment in determination of prognoses. These results reveal potential contributory factors behind different prognoses of OSCC patients with lymph node metastasis and provide reference for individual treatment planning.”
A new strategy could quell colorectal cancer metastasis to the liver
In the 2021 Cancer Cell publication “Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver,” Bertocchi et al. demonstrate that the PV-1 marker correlates with bacteria translocation and liver metastases and appears to serve as a prognostic marker for colorectal cancer distant recurrence and vascular impairment. This work offers insights into a new potential strategy to target tumor-associated bacteria to counteract liver metastases.